Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+53.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+53.6%/yr
vs +25.3%/yr prior
Acceleration
+28.3pp
Accelerating
Percentile
P100
Near historical high
vs 3Y Ago
3.6x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$22.52M+97.9%
2024$11.38M+69.0%
2023$6.73M+8.4%
2022$6.21M-
2021$0.00-
2020$0.00-
2019$0.00-100.0%
2018$2.52M+254.2%
2017$710375.00-3.3%
2016$734288.00-